Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay

被引:1
作者
Riva, Eloisa [1 ,2 ]
Garrido, David [2 ]
Villano, Fiorella [3 ]
Bove, Virginia [4 ]
机构
[1] Hosp Clin Montevideo, Montevideo, Uruguay
[2] Hosp Britan, Montevideo, Uruguay
[3] IAMPP, CASMU, Montevideo, Uruguay
[4] Hosp Cent FF AA, Montevideo, Uruguay
关键词
Infection; Multiple myeloma; Risk Factors; BACTERIAL-INFECTION; ERA; VACCINATION; SURVIVAL;
D O I
10.1016/j.htct.2023.09.2362
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Infections represent a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications in newly diagnosed MM (NDMM) patients are limited. Methods: We conducted a multicenter, prospective cohort study of patients with NDMM in Uruguay between June 2019 and December 2020. Patients with active disease, on active therapy and who provided written informed consent were included. Elegible patients were followed for 6 months from the time of diagnosis and before proceeding to autologous stem cell transplantation or until death, whichever occurred first. Our primary endpoint was the number of infectious events that required hospitalization for >= 24 h. Main results: Of 124 patients with NDMM, 54 (43.5 %) had infectious complications (74 infectious events), the majority (74.3 %) within the first 3 months from diagnosis. The most common sites of infection were urinary (39.2 %) and respiratory tracts (33.8 %). The microbial agent was identified in 60.8% of patients with Gram-negative bacteria (71.4 %) as the most common pathogen. Viral and fungal infections were infrequent. In the multivariable analysis, the Eastern Cooperative Oncology Group (ECOG) performance status was >= 2 (odds ratio [OR], 2.16; 95 % confidence interval [95 %CI], 1.23 - 3.79; p = 0.008) and creatinine >= 2 mg/dl (OR, 2.33; 95 %CI, 1.33 - 4.07; p = 0.003) were independent factors associated with bacterial infections. At 6 months, 14 patients (11.3 %) had died, 50 % related to infectious complications. Conclusion: Bacterial infections are a substantial cause of hospital admissions and early death in patients with NDMM. Antibiotic prophylaxis should be considered to reduce infectious complications in patients with MM. (c) 2023 Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license.
引用
收藏
页码:434 / 442
页数:9
相关论文
共 35 条
[1]   Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party [J].
Augustson, BM ;
Begum, G ;
Dunn, JA ;
Barth, NJ ;
Davies, F ;
Morgan, G ;
Behrens, J ;
Smith, A ;
Child, JA ;
Drayson, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9219-9226
[2]   Renal, hematologic and infectious complications in multiple myeloma [J].
Bladé, J ;
Rosiñol, L .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) :635-652
[3]   Renal failure in multiple myeloma -: Presenting features and predictors of outcome in 94 patients from a single institution [J].
Bladé, J ;
Fernández-Llama, P ;
Bosch, F ;
Montoliu, J ;
Lens, XM ;
Montoto, S ;
Cases, A ;
Darnell, A ;
Rozman, C ;
Montserrat, E .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (17) :1889-1893
[4]   Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients [J].
Blimark, Cecilie ;
Holmberg, Erik ;
Mellqvist, Ulf-Henrik ;
Landgren, Ola ;
Bjoekholm, Magnus ;
Hultcrantz, Malin ;
Kjellander, Christian ;
Turesson, Ingemar ;
Kristinsson, Sigurdur Y. .
HAEMATOLOGICA, 2015, 100 (01) :107-113
[5]   Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America [J].
Bove, Virginia ;
Riva, Eloisa ;
Vasquez, Jule ;
Pena, Camila ;
Seehaus, Cristian ;
Samanez, Cesar ;
Bustos, Justina ;
Hernandez, Marcos ;
Fernandez, Julio ;
Rios, Oliday ;
Rodriguez, Yusaima ;
Figueredo, Irving ;
Fantl, Dorotea ;
Malpica, Luis .
JCO GLOBAL ONCOLOGY, 2022, 8 :e2200068
[6]   The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey [J].
Brioli, Annamaria ;
Klaus, Maximilian ;
Sayer, Herbert ;
Scholl, Sebastian ;
Ernst, Thomas ;
Hilgendorf, Inken ;
Scherag, Andre ;
Yomade, Olaposi ;
Schilling, Kristina ;
Hochhaus, Andreas ;
Muegge, Lars-Olof ;
von Lilienfeld-Toal, Marie .
ANNALS OF HEMATOLOGY, 2019, 98 (03) :713-722
[7]   Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations [J].
Caravita, Tommaso ;
Offidani, Massimo ;
Siniscalchi, Agostina ;
Gentili, Silvia ;
Caraffa, Patrizia ;
Perrotti, Alessio ;
de Fabritiis, Paolo ;
Leoni, Pietro .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (03) :276-277
[8]   Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study [J].
Chanan-Khan, Asher ;
Sonneveld, Pieter ;
Schuster, Michael W. ;
Stadtmauer, Edward A. ;
Facon, Thierry ;
Harousseau, Jean-Luc ;
Ben-Yehuda, Dina ;
Lonial, Sagar ;
Goldschmidt, Hartmut ;
Reece, Donna ;
Neuwirth, Rachel ;
Anderson, Kenneth C. ;
Richardson, Paul G. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4784-4790
[9]   Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents [J].
Dimopoulos, M. A. ;
Delimpasi, S. ;
Katodritou, E. ;
Vassou, A. ;
Kyrtsonis, M. C. ;
Repousis, P. ;
Kartasis, Z. ;
Parcharidou, A. ;
Michael, M. ;
Michalis, E. ;
Gika, D. ;
Symeonidis, A. ;
Pouli, A. ;
Konstantopoulos, K. ;
Terpos, E. ;
Kastritis, E. .
ANNALS OF ONCOLOGY, 2014, 25 (01) :195-200
[10]   Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial [J].
Drayson, Mark T. ;
Bowcock, Stella ;
Planche, Tim ;
Iqbal, Gulnaz ;
Pratt, Guy ;
Yong, Kwee ;
Wood, Jill ;
Raynes, Kerry ;
Higgins, Helen ;
Dawkins, Bryony ;
Meads, David ;
Hulme, Claire T. ;
Monahan, Irene ;
Karunanithi, Kamaraj ;
Dignum, Helen ;
Belsham, Edward ;
Neilson, Jeff ;
Harrison, Beth ;
Lokare, Anand ;
Campbell, Gavin ;
Hamblin, Michael ;
Hawkey, Peter ;
Whittaker, Anna C. ;
Low, Eric ;
Dunn, Janet A. .
LANCET ONCOLOGY, 2019, 20 (12) :1760-1772